Good cardiac safety in patients with relapsing remitting multiple sclerosis upon first fingolimod dose

Volker Limmroth1, Susanne Hoyer2, Stephan Schmidt3, Michael Lang4, Tjalf Ziemssen5
1 Neurologische Klinik, Kliniken der Stadt Köln, Cologne, Germany; 2 Novartis Pharma GmbH, Nuremberg, Germany; 3 NTD Study Group, Neurologische Gemeinschaftspraxis, Bonn, Germany; 4 NTD Study Group, Neurologische Praxis, Ulm, Germany; 5 Neurologische Klinik, Universität Dresden, Dresden, Germany

Conclusion
• 99.3% of patients had no bradycardia (< 45bpm), 100% of patients had no QTcF-interval prolongation (≥ 500 msec), 98.4% of patients had no AV Block II0 or higher approx. 7 days after treatment initiation.

Methods
• The START study is a prospective, 1-week, multicenter, open-label study enrolling up to 7,000 RRMS patients in more than 250 centers in Germany, according to the EU label criteria of fingolimod.

Results
• The second START interim-analysis is based on 1,230 patients for most analyses.

Table 2: QTcF-intervals after treatment initiation

<table>
<thead>
<tr>
<th>Patients with SSRI (n = 113)</th>
<th>Patients with AV Block II0 or higher after treatment initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>QTcF-interval &lt; 500 msec</td>
<td>100%</td>
</tr>
<tr>
<td>QTcF-interval ≥ 500 msec</td>
<td>0%</td>
</tr>
</tbody>
</table>

Volker Limmroth:
Bayer Health Care, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis and TEVA

Conflicts of interest
The following authors have received support for research activities or the institutions for which they work received support for research projects from the following companies and establishments: F. Hoffmann-La Roche, Genzyme, Merck, Novartis, Biogen, Bayer, Teva, Serono, Idec, Genzyme, Merck Serono, and Teva Pharma.

References